Literature DB >> 21443470

Biology of Cox-2: an application in cancer therapeutics.

Zakir Khan1, Noor Khan, Ram P Tiwari, Nand K Sah, G B K S Prasad, Prakash S Bisen.   

Abstract

Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443470     DOI: 10.2174/138945011795677764

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  50 in total

Review 1.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

2.  Low expression of microRNA-143 is related to degenerative scoliosis possibly by regulation of cyclooxygenase-2 expression.

Authors:  Jie Zheng; Yonghong Yang; Kefeng Zhao; Ran Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Nikolaos Tsoukalas; Ioannis Sfiniadakis; Nikolaos Kavantzas; Emmanuel Agapitos; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2014-09-25

4.  Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Authors:  Constantinos Giaginis; Anastasia Sampani; Iolly Kotta-Loizou; Ioanna Giannopoulou; Eugene Danas; Ekaterini Politi; Gerasimos Tsourouflis; Gregorios Kouraklis; Efstratios Patsouris; Antonios Keramopoulos; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2017-08-14       Impact factor: 3.201

5.  Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.

Authors:  Yanmei Zhang; Micky D Tortorella; Jinxi Liao; Xiaochu Qin; Tingting Chen; Jinfeng Luo; Jiantong Guan; John J Talley; Zhengchao Tu
Journal:  ACS Med Chem Lett       Date:  2015-09-08       Impact factor: 4.345

6.  Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Authors:  Md Jashim Uddin; Brenda C Crews; Shu Xu; Kebreab Ghebreselasie; Cristina K Daniel; Philip J Kingsley; Surajit Banerjee; Lawrence J Marnett
Journal:  ACS Chem Biol       Date:  2016-09-19       Impact factor: 5.100

Review 7.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

8.  Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Authors:  Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen
Journal:  Clin Cancer Res       Date:  2013-02-19       Impact factor: 12.531

9.  Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo.

Authors:  Hai-Xia Qin; Jun Yang; Hong-Kai Cui; Shao-Ping Li; Wei Zhang; Xiao-Li Ding; Yong-Hua Xia
Journal:  Cytotechnology       Date:  2013-03-10       Impact factor: 2.058

10.  Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis.

Authors:  Di Wang; Xiao-Zhong Guo; Hong-Yu Li; Jia-Jun Zhao; Xiao-Dong Shao; Chun-Yan Wu
Journal:  Tumour Biol       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.